Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy
- 1 February 1995
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 132 (2) , 257-262
- https://doi.org/10.1111/j.1365-2133.1995.tb05022.x
Abstract
We have previously shown that cimetidine, given concurrently for 2 weeks to patients on chronic dapsone therapy, reduced methaemoglobinaemia by inhibiting the formation of the toxic hydro-xylamine metabolite of dapsone. The aim of the present study was to examine the effect of this combination on the benefit/toxic ratio of dapsone over a longer period. Eight patients (six dermatitis herpetiformis, one linear IgA disease, one folliculitis decalvans) on long-term dapsone 50-100 mg daily, took cimetidine 1·6g daily concurrently for 3 months. At 3-weekly intervals, a clinical assessment was made, plasma dapsone and methaemoglobin were measured, and parameters of oxidative haemolysis were monitored. The dapsone level rose from 2298±849 ng/ml (mean+SD) at baseline to 3006±1131 ng/ml at week 3 of cimetidine (PPPPP<0·05), but this was not associated with any deterioration in control of the skin disorders. Hence, long-term concurrent cimetidine results in increased plasma dapsone levels without increased haemolysis, and is accompanied by reduced methaemoglobinaemia for more than 2 months. Cimetidine thus improves the therapeutic/toxic ratio of dapsone. Such a therapeutic strategy may be appropriate for patients who require high-dose dapsone, or those who are particularly susceptible to dapsone-induced haemotoxicity.Keywords
This publication has 21 references indexed in Scilit:
- Dapsone-Pyrimethamine Compared with Aerosolized Pentamidine as Primary Prophylaxis against Pneumocystis carinii Pneumonia and Toxoplasmosis in HIV InfectionNew England Journal of Medicine, 1993
- The use of cimetidine to reduce dapsone‐dependent methaemoglobinaemia in dermatitis herpetiformis patients.British Journal of Clinical Pharmacology, 1992
- Differential inhibition of individual human liver cytochromes P-450 by cimetidineGastroenterology, 1991
- The effect of preincubation with cimetidine on the N‐hydroxylation of dapsone by human liver microsomes.British Journal of Clinical Pharmacology, 1991
- Dermatitis herpetiformisCurrent Problems in Dermatology, 1991
- The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjectsClinical Pharmacology & Therapeutics, 1990
- The use of cimetidine as a selective inhibitor of dapsone N‐ hydroxylation in man.British Journal of Clinical Pharmacology, 1990
- Clinical Pharmacokinetics of DapsoneClinical Pharmacokinetics, 1986
- Sulfones and sulfonamides in dermatology todayJournal of the American Academy of Dermatology, 1979
- Microsomal N-Oxidation of Dapsone as a Cause of Methemoglobin Formation in Human Red Cells *The American Journal of Tropical Medicine and Hygiene, 1972